Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Seonggyu Byeon; Youjin Kim; Sung Won Lim; Jang Ho Cho; Sehoon Park; Jiyun Lee; Jong-Mu Sun; Yoon-La Choi; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn

doi:10.4143/crt.2018.151

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(2); 2019 > Article

Original Article Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea: Seonggyu Byeon, MD¹, Youjin Kim, MD¹, Sung Won Lim, MD¹, Jang Ho Cho, MD¹, Sehoon Park, MD¹, Jiyun Lee¹, Jong-Mu Sun, MD, PhD¹, Yoon-La Choi, MD, PhD², Se-Hoon Lee, MD, PhD¹, Jin Seok Ahn, MD, PhD¹, Keunchil Park, MD, PhD¹, Myung-Ju Ahn, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(2):623-631.
DOI: https://doi.org/10.4143/crt.2018.151
Published online: July 23, 2018

¹Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: Myung-Ju Ahn, MD, PhD Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-3452 Fax: 82-2-3410-1754 E-mail: silk.ahn@samsung.com

• Received: March 12, 2018 • Accepted: July 19, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

16,233 Views
699 Download
43 Web of Science
37 Crossref
46 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully established.
Materials and Methods
Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy.
Results
Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advancedNSCLC patients. The 22 patientswho received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progressionfree survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The othertwo patients had an exon 20 insertion and another EGFR mutation and achieved a partial response.
Conclusion
The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to firstor second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.
Key words: Non-small cell lung cancer, Exon 20 insertion, Epidermal growth factor receptor, Mutation, EGFR tyrosine kinase inhibitor

Introduction

Lung cancer is a leading cause of cancer death worldwide [1,2]. In Korea, 24,000 cases are newly diagnosed, and 17,440 patients die of lung cancer each year [2]. Approximately 80-85% of lung cancers are classified as non-small cell lung cancer (NSCLC) [3]. The discovery of relevant genomic abnormalities in NSCLC has led to the development of novel, targeted chemotherapeutic agents. It has also caused a paradigm shift in the treatment of NSCLC, particularly for those with non-squamous cell carcinoma. Epidermal growth factor receptor (EGFR) mutations represent the most prevalent drug-treatable targets and are detected in approximately 40% of NSCLC cases in Asian patients, and in 10%-20% of cases in Caucasian patients [4,5]. EGFR mutations are commonly found in never-smokers, females, and patients with adenocarcinoma. The most common activating EGFR mutations include an in-frame deletion in exon 19 and the L858R mutation in exon 21. Together, these account for 90% of EGFR mutations [6].

EGFR tyrosine kinase inhibitors (TKIs) are associated with a highly effective and durable response in NSCLC patients with these common EGFR mutations, often yielding 9-13 months of progression-free survival (PFS) and more than 24 months of overall survival (OS) [7-9]. Other, less commonly observed EGFRmutations (such as G719X or L861Q) account for 2%-3% of EGFR mutations and are also considered responsive to EGFR TKIs [10].

EGFR exon 20 insertion mutations are typically located just after the C-helix of the tyrosine kinase domain of EGFR, and their incidence varies between 1% to 9% of all EGFR mutations [11-15]. Given the rarity of these mutations and the fact they are mostly studied in surgically resected patients, the clinical characteristics and outcomes of advanced NSCLC patients with EGFR exon 20 insertion mutations have not been fully established.

Materials and Methods

1. Patients

Between January 2009 and December 2017, histologically confirmed Samsung Medical Center NSCLC patients with activating EGFR mutations were selected from an institutional database. Among them, patients with an EGFR exon 20 insertion mutation were retrospectively analyzed for clinicopathological characteristics, responses to systemic chemotherapy or targeted agents, PFS, and OS.

2. EGFR mutation tests

Mutational analyses of EGFR (exons 18-21) were performed as previously described by directional sequencing, by the peptide nucleic acid clamp method, or by next-generation sequencing [16].

3. Statistical analysis

All available data were retrospectively collected using a standardized case report form. OS and PFS were calculated using the Kaplan-Meier method. The Cox proportional hazards regression model was used to evaluate the impact of collected variables on PFS and OS. Two-sided p-values were set at a 0.05 significance level. All analyses were performed using SPSS ver. 23.0 software (IBM Corp., Armonk, NY).

4. Ethical statement

Institutional Review Board (IRB) approval was obtained from Samsung Medical Center (SMC, Seoul, Korea, SMC 2018-02-019). The IRB approved waiver of informed consent.

Results

1. Prevalence of EGFR mutations

From January 2009 to December 2017, 3,539 patients showed positive results in the EGFR mutation test. Among them, 1,712 (48.3%) had an exon 19 deletion, 1,451 (41.0%) had L858R, 132 (3.7%) had G719X, 92 (2.6%) had L861Q, 56 (1.6%) had an exon 20 insertion, and 34 (1.0%) had S768I (S1 Fig.). Among the 56 patients with an exon 20 insertion, eight had an additional mutation: four had an exon 19 deletion, two had L858R, one had G719S, and one had S768I.

Of the 3,539 total patients, 1,479 had advanced NSCLC. These patients included 752 (50.8%) with an exon 19 deletion, 557 (37.7%) with L858R, 49 (3.3%) with G719X, 49 (3.3%) with L861Q, 27 (1.8%) with an exon 20 insertion, and 17 (1.1%) with S768I (Fig. 1).

2. Characteristics of patients with exon 20 insertion mutation

Among total 3,539 patients, 3,163 patients were identified that having common EGFR mutations, meanwhile 376 patients were uncommon EGFR mutations. Demographic characteristics of total 3,539 patients were summarized in Table 1. Women, adenocarcinoma, and early staged NSCLC patients were more common in NSCLC patients with common EGFR mutations.

Baseline characteristics of 27 advanced NSCLC patients harboring an exon 20 insertion mutation are summarized in Table 2. The median follow-up duration was 12.1 months (range, 0.9 to 62.4 months). The median age at diagnosis was 60 years (range, 43 to 75 years), and 41% of patients were female. A majority of patients (78%) were never-smokers, and most (96%) had adenocarcinoma. The most common metastatic sites were the central nervous system (40.7%), lung (33.3%), bone (33.3%), and liver (18.5%). Of note, 23 patients had only an exon 20 insertion mutation, while four patients had an additional activating mutation: two had L858R, one had S768I, and one had G719S (Table 2).

3. Types of exon 20 insertion mutations

Among 27 patients with exon 20 insertions, only 17 had available data for amino acid position changes. All exon 20 insertions were clustered between Val769 and Val775. His-773_Val774insHis was the most common insertion mutation (n=7, 41.2%), followed by Val774_Cys775insHisVal (n=3, 17.7%) and His773_Val774insProHis (n=2, 11.7%). Each of the following mutations was found one time: His773_Val-774insAsnProHis, Pro772_His773insThrThrPro, Pro772_ His-773insGlyAsnPro, Val769_Asn771insValGlyVal, and Asp-770_Asn771insGly (Table 3).

4. Treatment responses and clinical outcomes

Of the 27 patients with exon 20 insertions, 22 received platinum-based systemic chemotherapy. The overall response rate (ORR) was 50.0%, and the disease control rate was 77.2%. The median PFS was 4.2 months (95% confidence interval [CI], 1.7 to 6.6), and the median OS was 29.4 months (95% CI, 9.3 to 49.6) (Fig. 2). In contrast, all patients with a double mutation were still alive at the time of last follow-up (November 15, 2017; OS range, 2.2 to 15.0 months). A Cox proportional regression analysis revealed that central nervous system metastasis was associated with poor OS (p=0.043, data not shown).

Six patients were treated with an EGFR TKI. Three patients received a reversible EGFR TKI (erlotinib), and the other three received an irreversible EGFR TKI (two received afatinib, and one received osimertinib). Among the four patients with only an exon 20 insertion, three had progressive disease and one had stable disease. In contrast, the two doublemutation patients achieved a partial response to treatment (Table 4).

Discussion

We found that exon 20 insertion mutations represented 1.6% of all EGFR mutations, regardless of the cancer stage. Exon 20 insertions represented 1.8% of the EGFR mutations found in cases of advanced NSCLC, consistent with previous reports [6,11,12,14]. These patients shared similar characteristics with patients harboring other common EGFR mutations in that the majority had adenocarcinoma (96%) and were never-smokers (78%).

Amino acid sequencing data from the exon 20 insertion mutations indicated that the majority (88.2%) showed changes after His773. The most frequent amino acid change was His773_Val774insHis (41.1%), followed by Val774_Cys-775insHisVal (17.6%) and His773_Val774insProHis (11.7%). All amino acid changes occurred between Val769 and Val-775, in a region located just after the C-helix of the EGFR tyrosine kinase domain. These findings are consistent with the results of Yasuda et al. [17]. We observed three novel amino acid sequence variants: Pro772_His773insGlyAsnPro, Val769_Asn771insValGlyVal, and Pro772_His773insThrThr-Pro. This suggests that exon 20 insertion mutations are highly variable and heterogeneous. Although the clinical significance of these novel sequences has not been established, efforts to find new amino acid sequences in exon 20 mutations are warranted.

It has been suggested that exon 20 insertions and other types of EGFR mutations are mutually exclusive [11-14,16]. Among the 56 patients with exon 20 insertions in our study, eight had an additional EGFR mutation to the exon 20 insertion, such as L858R, an exon 19 deletion, S768I, or G719S. Patients with a double mutation comprising an exon 20 insertion and L858R or G719S initially achieved a partial response to EGFR TKIs. However, the PFS was short (1.9-2.9 months), suggesting that exon 20 insertion might be dominant over the other more common mutation. Further validation of these results is needed. As expected, patients with an exon 20 insertion only who received EGFR TKIs had a low response rate and short PFS (~2.6 months; range, 0.7 to 11.4), consistent with previous reports [12,14,15,20].

One patient showed a long duration of stable disease following treatment with an EGFR TKI. Some exon 20 insertions (such as A763_Y764insFQEA) are relatively sensitive to EGFR TKIs, and this patient may have had such a variant [12,21].

In general, exon 20 insertion mutation in NSCLC is associated with lack of sensitivity to first-generation EGFR TKIs, such as erlotinib or gefitinib [12-14,18,19], and so does our study (Table 5). The exact mechanism underlying this lack of sensitivity has not been fully established. It is possible that exon 20 insertions occurring after the C-helix might induce conformational changes that affect the binding affinity to EGFR inhibitors, promoting resistance to EGFR TKIs [17]. Kosaka et al. showed that replacing Asp770 with Gly770 restored sensitivity to EGFR TKIs by allowing Arg776 access. This facilitated a C-helix conformational change and substrate binding in Ba/F3 cells transduced with an EGFR exon 20 insertion mutation [22].

In one pre-clinical study, patient derived xenografts cells harboring an EGFR exon 20 insertion showed a partial response to second-generation (afatinib) and third-generation (osimertinib and rociletinib) TKIs [23]. Another pre-clinical study showed that a novel, mutant-selective inhibitor of EGFR (nazartinib) showed promising results in vitro in cancer-derived cell lines expressing exon 20 insertions. Nazartinib was effective for the duration of the therapeutic window, at only half the maximal inhibitory concentration (IC₅₀) [24]. But in clinical trials to date, promising results have not been observed with currently available agents designed to target EGFR [25,26]. Therefore, further studies are needed to enhance our understanding of the EGFR structure and to clarify the mechanisms by which exon 20 insertions affect patient responses to EGFR TKIs. As part of these efforts, one phase II study of poziotinib in patients with advanced NSCLC and EGFR exon 20 mutations had been conducted. In this study, seven of 11 patients achieved a partial response to poziotinib, suggesting its promising efficacy [27].

In this study, the advanced NSCLC patients with exon 20 insertion had median OS of 29.4 months (95% CI, 9.3 to 49.6), which is consistent with median OS of advanced NSCLC with common EGFR mutations [8,9]. The ORR and PFS to platinum-based chemotherapy were 50% and 4.2 months, respectively. Considering the poor outcomes with EGFR TKIs, platinum-based systemic chemotherapy is considered standard treatment for advanced NSCLC with an exon 20 insertion mutation [12,20].

The present study has certain limitations. Given the small number of patients and retrospective nature of the analysis, patients analyzed in this cohort might not be representative of all types of advanced NSCLC with EGFR exon 20 insertion mutations. Furthermore, the various techniques used in this study to detect EGFR mutations have inherently different levels of specificity and sensitivity. Nevertheless, we analyzed one of the largest cohorts of its kind, with more than 3,000 patients with activating EGFR mutations.

In conclusion, exon 20 insertion mutations are rare in Korea, and are occasionally accompanied by common EGFR mutations. Although the response to systemic chemotherapy in these patients is comparable to that in patients with more common EGFR mutations, the response rate to first- or second-generation EGFR TKIs is quite low. For this reason, the development of a more efficient chemotherapeutic agent is urgently needed.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2018-151-suppl.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Distribution of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer patients (n=1,479).

Fig. 2.

Kaplan-Meier survival curves. (A) Progression-free survival of patients with an exon 20 insertion receiving systemic chemotherapy. (B) Overall survival of patients with an exon 20 insertion. NSCLC, non-small cell lung cancer.

Table 1.

Clinical characteristics of total 3,539 patients with NSCLC

	Common (n=3,163)	Uncommon (n=376)	p-value
Age at diagnosis (yr)	61 (19-92)	62 (27-87)	NS
Sex
Female	2,008 (63.5)	217 (57.7)	0.032
Male	1,155 (36.5)	159 (42.3)
Histology
ADC	3,077 (97.3)	335 (89.1)	< 0.001
SqCC	47 (1.5)	20 (5.3)
Others	39 (1.2)	21 (5.6)
Stage
I-IIIA	1,866 (59.0)	194 (51.6)	0.007
IIIB-IV	1,297 (41.0)	182 (48.4)

Values are presented as median (range) or number (%). NSCLC, non-small cell lung cancer; NS, non-significant; ADC, adenocarcinoma; SqCC, squamous cell carcinoma.

Table 2.

Baseline characteristics of patients with an exon 20 insertion mutation

	Early-stage (n=29)	Refractory NSCLC (n=27)	Total (n=56)
Age at diagnosis (yr)	60 (36-78)	60 (43-75)	60 (36-78)
Sex
Female	14 (48.2)	11 (40.7)	25 (44.6)
Male	15 (51.8)	16 (59.3)	33 (55.4)
Histology
ADC	29 (100)	26 (96.3)	55 (98.2)
SqCC	0	1 (3.7)	1 (1.8)
ECOG
0	8 (27.6)	1 (3.8)	9 (16.1)
1	21 (72.4)	19 (70.3)	40 (71.4)
2	0	7 (25.9)	7 (12.5)
Smoking history
Never	19 (65.5)	21 (77.8)	40 (71.4)
Current	6 (20.7)	3 (11.1)	9 (16)
Ex	4 (13.8)	3 (11.1)	7 (12.6)
Metastasis
CNS	-	11	-
Bone	-	9	-
Liver	-	5	-
Lung	-	9	-
Exon 20 mutation
Insertion only	25 (8-6.2)	23 (85.2)	-
Double mutation
Insertion+S768I	-	1 (3.7)	-
Insertion+G719S	-	1 (3.7)	-
Insertion+Deletion 19	4 (13.8)	-	-
Insertion+L858R	-	2 (7.4)	-

Values are presented as median (range) or number (%). NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SqCC, squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group; CNS, central nervous system.

Table 3.

Amino acid sequences of 17 NSCLC patients with an exon 20 insertion

No.	Sex	Age (yr)	Smoking Hx	ECOG	Initial stage	Exon 20 mutation	EGFR TKI	Chemotherapy	Best response	PFS	OS
1	F	58	Never	1	IIIA	c.2319_2320 ins CAC (p.H773_V774insH)	N/A	Premetrexed+cisplatin	SD	17.0	46.4
2	M	73	Never	2	IA	c.2319_2320 ins CAC (p.H773_V774insH)	N/A	N/A			44.8
3	M	75	Never	1	IV	C.2316_2317 ins GGCAACCCC (p.P772_H773insGNP)	N/A	Premetrexed+cisplatin	SD	2.7	3.8
4	M	63	Never	1	IIIA	c.2319_2320 ins CCCCAC (p.H773_V774insH)	N/A	Paclitaxel+cisplatin	PD	0.9	9.7
5	M	50	Never	1	IB	c.2305_2313 ins GTGGGGGTC (p.V769_N771insVGV)	N/A	N/A			22.5
6	F	55	Never	1	IV	c.2310_2311 ins GGT (p.D770_N771insG)	N/A	Premetrexed+cisplatin	PD	1.9	6.1
7	F	63	Never	2	IV	c.2322_2323 ins CACGTG (p.V774_C775insHV)	N/A	Premetrexed+cisplatin	SD	2.1	18.4
8	F	55	Never	1	IA	c.2322_2323 ins CACGTG (p.V774_C775insHV)	N/A	Premetrexed+cisplatin	PR	13.0	26.2
9	F	56	Never	1	IIIA	c.2319_2320 ins AACCCCCAC (p.H773_V774insNPH)	N/A	Docetaxel+cisplatin	PR	2.7	29.5
10	M	60	Never	2	IB	c.2319_2320 ins CCCCAC (p.H773_V774insPH	N/A	Premetrexed+cisplatin	PR	2.6	46.4
11	M	48	Never	2	IV	c.2315_2316 ins GACAACCCC (p.P772_H773insTTP)	N/A	Premetrexed+cisplatin	PR	2.4	12.4
12	F	62	Never	1	IA	c.2321_2322 ins CCACGT (p.V774_C775insHV)	N/A	N/A			44.1
13	F	52	Never	1	IA	c.2319_2320insCAC (p.H773_V774insH)	N/A	N/A			35.2
14	M	60	Never	1	IIIA	c.2319_2320insCAC (p.H773_V774insH)	N/A	Etoposide+cisplatin	PD	2.6	25.9
15	M	60	Never	1	IIIA	c.2319_2320insCAC (p.H773_V774insH)	N/A	Etoposide+cisplatin	SD	17.2	26.2
16	F	66	Never	1	IIIA	c.2318_2319 ins TAACCCCAG (p.H773_V774insPH)	N/A	Premetrexed+cisplatin	SD	2.8	62.4
17	M	65	Never	1	IA	c.2319_2320insCAC (p.H773_V774insH)	N/A	Premetrexed+cisplatin	PR	2.9	36.9

The most frequent amino acid change was His773_Val774insHis (41.1%), followed by Val774_Cys775insHisVal (17.6%) and His773_Val774insProHis (11.7%).

NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; ECOG, Eastern Cooperative Oncology Group; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; F, female; N/A, not available; M, male; SD, stable disease; PD, progressive disease; PR, partial response.

Table 4.

Clinical information and treatment outcomes of six patients who received EGFR TKIs

Sex	Age (yr)	Exon 20 type	ECOG	Smoking history	Initial stage	TKI type	EGFR TKI response	PFS
F	44	Insertion	1	Never-smoker	IV	Erlotinib	PD	0.7
M	65	Insertion	2	Never-smoker	IV	Afatinib	PD	0.9
M	60	Insertion	1	Current smoker 30PY	IV	Erlotinib	PD	2.6
M	48	Insertion	0	Ex-smoker 20PY	IV	Erlotinib	SD	11.4
M	62	Insertion+L858R	1	Ex-smoker 10PY	IIB	Afatinib	PR	1.9
F	43	Insertion+G719S	1	Never-smoker	IV	Osimertinib	PR	2.8

EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; F, female; M, male; PD, progressive disease; SD, stable disease; PR, partial response.

Table 5.

Published studies evaluating clinical response to EGFR TKIs in NSCLC patients with exon 20 insertion

Study	Type of EGFR Exon 20 mutation	Patients treated with EGFR TKIs	ORR to TKI (%)	PFS to TKI	OS
Tu et al. [18]	Insertion 20	12	0	3.0 (1.3-4.7)	12.5 (0-25.5)
Lund-Iversen et al. [13]	Insertion 20	3	0	-	-
Arcila et al. [15]	Insertion 20	5	40	2.5	> 48 mo
Naidoo et al. [12]	Insertion 20	11	27	-	-
Yasuda et al. [17]	Insertion 20	19	11	-	-
Kuiper et al. [19]	Insertion 20	16	0	2.9 (2.3-3.6)	9.7
Current study	Insertion 20	4	25	2.6 (0.7-11.4)	29.4 (9.3-49.6)

EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression free survival; OS, overall survival.

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. Article PubMed
2. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305. Article PubMed PMC PDF
3. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165–72. Article PubMed PMC
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39. Article PubMed
5. Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, et al. Successful rechallenge with erlotinib in a patient with EGFR mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol. 2010;65:803–6. Article PubMed
6. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67. Article PubMed
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42. Article PubMed
8. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. Article PubMed
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57. Article PubMed
10. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760–74. Article PubMed PMC PDF
11. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14:4877–82. Article PubMed
12. Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121:3212–20. Article PubMed PMC
13. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun OT. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol. 2012;7:1471–3. Article PubMed
14. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metellus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25:126–31. Article PubMed PDF
15. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220–9. Article PubMed PMC
16. Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, et al. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Cancer Chemother Pharmacol. 2014;73:1063–70. Article PubMed
17. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5:216ra177.Article PubMed PMC
18. Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017;114:96–102. Article PubMed
19. Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grunberg K, Bloemena E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer. 2016;115:1504–12. Article PubMed PMC PDF
20. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179–84. Article PubMed PMC
21. Lin YT, Liu YN, Wu SG, Yang JC, Shih JY. Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced nonsmall-cell lung cancer. Clin Lung Cancer. 2017;18:324–32. Article PubMed
22. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, et al. Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res. 2017;77:2712–21. Article PubMed PMC
23. Yang M, Xu X, Cai J, Ning J, Wery JP, Li QX. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors. Int J Cancer. 2016;139:171–6. Article PubMed
24. Masuzawa K, Yasuda H, Hamamoto J, Nukaga S, Hirano T, Kawada I, et al. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget. 2017;8:105479–91. Article PubMed PMC
25. Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC, Chen WC, et al. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017;110:56–62. Article PubMed
26. Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17:1131–9. Article PubMed PMC
27. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24:638–46. Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Pasi A. Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W. Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Hua
Journal of Clinical Oncology.2025;[Epub] CrossRef
Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
Clinical Lung Cancer.2024; 25(2): 100. CrossRef
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
BMC Proceedings.2024;[Epub] CrossRef
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu
Lung Cancer.2024; 191: 107798. CrossRef
The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
Xiuyue Man, Xueru Sun, Chen Chen, Yan Xiang, Jing Zhang, Lei Yang
Frontiers in Oncology.2024;[Epub] CrossRef
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukb
Journal of Cancer Research and Clinical Oncology.2023; 149(2): 865. CrossRef
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
Lung Cancer.2023; 179: 107186. CrossRef
EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron D. Bossler, Deqin Ma
Frontiers in Oncology.2023;[Epub] CrossRef
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
Ying-Ting Liao, Lei-Chi Wang, Ruei-Lin Sun, Yi-Chen Yeh, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Tsu-Hui Hsiao, Heng-Sheng Chao, Yung-Hung Luo, Yuh-Min Chen, Chi-Lu Chiang
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10365. CrossRef
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Qianming Bai, Jialei Wang, Xiaoyan Zhou
Cancer Treatment Reviews.2023; 120: 102605. CrossRef
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
Cancer Treatment Reviews.2023; 120: 102628. CrossRef
Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
Thoracic Cancer.2023; 14(33): 3247. CrossRef
Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
Youjun Deng, Chenglin Yang, Wenyi Liu, Songhua Cai, Xiaotong Guo
Anti-Cancer Drugs.2022; 33(4): 406. CrossRef
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
Neeraj Gupta, Philippe B. Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen
CPT: Pharmacometrics & Systems Pharmacology.2022; 11(6): 731. CrossRef
Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
Timothée Olivier, Vinay Prasad
Translational Oncology.2022; 23: 101475. CrossRef
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
Cancer Cell.2022; 40(7): 754. CrossRef
EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang
Frontiers in Pharmacology.2022;[Epub] CrossRef
The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
Journal of Modern Oncology.2022; 24(3): 340. CrossRef
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Maria Garcia Campelo, Caicun Zhou, Suresh Ramalingam, Huamao Lin, Tae Kim, Gregory Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, Sanjay Popat, Pasi Jänne
Journal of Clinical Medicine.2022; 12(1): 112. CrossRef
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
Guang-Jian Yang, Jun Li, Hai-Yan Xu, Yang Sun, Liu Liu, Hong-Shuai Li, Lu Yang, Yuan Zhang, Guo-Hui Li, Yan Wang
Lung Cancer.2021; 152: 39. CrossRef
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li, Rama Krishna Kancha
PLOS ONE.2021; 16(3): e0247620. CrossRef
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
Clinical Cancer Research.2021; 27(10): 2920. CrossRef
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M. Wright, Steven Kao, Brett G.M. Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John
Clinical Lung Cancer.2021; 22(6): e859. CrossRef
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylv
Cancer Discovery.2021; 11(7): 1688. CrossRef
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Scientific Reports.2021;[Epub] CrossRef
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
Cancers.2021; 13(20): 5132. CrossRef
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria R. Garcia Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao M. Li
JAMA Oncology.2021; 7(12): e214761. CrossRef
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale DUBRAY-Longeras, Sandrine H
Targeted Oncology.2021; 16(6): 801. CrossRef
External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
Sze Yee Chai, Rongxue Peng, Rui Zhang, Li Zhou, Nalishia Pillay, Kwang Hong Tay, Tony Badrick, Jinming Li, Martin P. Horan
Pathology & Oncology Research.2020; 26(3): 1595. CrossRef
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen
Lung Cancer.2020; 141: 9. CrossRef
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, Yapin Li, Weini Qiu, Jianming Ying, Sai-Hong Ignatius Ou, Yan Wang
Lung Cancer.2020; 145: 186. CrossRef
Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
Molecular Oncology.2020; 14(8): 1695. CrossRef
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain
Lung Cancer.2020; 149: 53. CrossRef
Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih
Clinical Lung Cancer.2019; 20(6): e620. CrossRef
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
BMC Cancer.2019;[Epub] CrossRef
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Ya Gao, Wies R. Vallentgoed, Pim J. French
Cancers.2018; 10(12): 489. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Cancer Res Treat. 2019;51(2):623-631. Published online July 23, 2018

DOI: https://doi.org/10.4143/crt.2018.151

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Fig. 1. Distribution of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer patients (n=1,479).

Fig. 2. Kaplan-Meier survival curves. (A) Progression-free survival of patients with an exon 20 insertion receiving systemic chemotherapy. (B) Overall survival of patients with an exon 20 insertion. NSCLC, non-small cell lung cancer.

Fig. 1.

Fig. 2.

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

	Common (n=3,163)	Uncommon (n=376)	p-value
Age at diagnosis (yr)	61 (19-92)	62 (27-87)	NS
Sex
Female	2,008 (63.5)	217 (57.7)	0.032
Male	1,155 (36.5)	159 (42.3)
Histology
ADC	3,077 (97.3)	335 (89.1)	< 0.001
SqCC	47 (1.5)	20 (5.3)
Others	39 (1.2)	21 (5.6)
Stage
I-IIIA	1,866 (59.0)	194 (51.6)	0.007
IIIB-IV	1,297 (41.0)	182 (48.4)

	Early-stage (n=29)	Refractory NSCLC (n=27)	Total (n=56)
Age at diagnosis (yr)	60 (36-78)	60 (43-75)	60 (36-78)
Sex
Female	14 (48.2)	11 (40.7)	25 (44.6)
Male	15 (51.8)	16 (59.3)	33 (55.4)
Histology
ADC	29 (100)	26 (96.3)	55 (98.2)
SqCC	0	1 (3.7)	1 (1.8)
ECOG
0	8 (27.6)	1 (3.8)	9 (16.1)
1	21 (72.4)	19 (70.3)	40 (71.4)
2	0	7 (25.9)	7 (12.5)
Smoking history
Never	19 (65.5)	21 (77.8)	40 (71.4)
Current	6 (20.7)	3 (11.1)	9 (16)
Ex	4 (13.8)	3 (11.1)	7 (12.6)
Metastasis
CNS	-	11	-
Bone	-	9	-
Liver	-	5	-
Lung	-	9	-
Exon 20 mutation
Insertion only	25 (8-6.2)	23 (85.2)	-
Double mutation
Insertion+S768I	-	1 (3.7)	-
Insertion+G719S	-	1 (3.7)	-
Insertion+Deletion 19	4 (13.8)	-	-
Insertion+L858R	-	2 (7.4)	-

No.	Sex	Age (yr)	Smoking Hx	ECOG	Initial stage	Exon 20 mutation	EGFR TKI	Chemotherapy	Best response	PFS	OS
1	F	58	Never	1	IIIA	c.2319_2320 ins CAC (p.H773_V774insH)	N/A	Premetrexed+cisplatin	SD	17.0	46.4
2	M	73	Never	2	IA	c.2319_2320 ins CAC (p.H773_V774insH)	N/A	N/A			44.8
3	M	75	Never	1	IV	C.2316_2317 ins GGCAACCCC (p.P772_H773insGNP)	N/A	Premetrexed+cisplatin	SD	2.7	3.8
4	M	63	Never	1	IIIA	c.2319_2320 ins CCCCAC (p.H773_V774insH)	N/A	Paclitaxel+cisplatin	PD	0.9	9.7
5	M	50	Never	1	IB	c.2305_2313 ins GTGGGGGTC (p.V769_N771insVGV)	N/A	N/A			22.5
6	F	55	Never	1	IV	c.2310_2311 ins GGT (p.D770_N771insG)	N/A	Premetrexed+cisplatin	PD	1.9	6.1
7	F	63	Never	2	IV	c.2322_2323 ins CACGTG (p.V774_C775insHV)	N/A	Premetrexed+cisplatin	SD	2.1	18.4
8	F	55	Never	1	IA	c.2322_2323 ins CACGTG (p.V774_C775insHV)	N/A	Premetrexed+cisplatin	PR	13.0	26.2
9	F	56	Never	1	IIIA	c.2319_2320 ins AACCCCCAC (p.H773_V774insNPH)	N/A	Docetaxel+cisplatin	PR	2.7	29.5
10	M	60	Never	2	IB	c.2319_2320 ins CCCCAC (p.H773_V774insPH	N/A	Premetrexed+cisplatin	PR	2.6	46.4
11	M	48	Never	2	IV	c.2315_2316 ins GACAACCCC (p.P772_H773insTTP)	N/A	Premetrexed+cisplatin	PR	2.4	12.4
12	F	62	Never	1	IA	c.2321_2322 ins CCACGT (p.V774_C775insHV)	N/A	N/A			44.1
13	F	52	Never	1	IA	c.2319_2320insCAC (p.H773_V774insH)	N/A	N/A			35.2
14	M	60	Never	1	IIIA	c.2319_2320insCAC (p.H773_V774insH)	N/A	Etoposide+cisplatin	PD	2.6	25.9
15	M	60	Never	1	IIIA	c.2319_2320insCAC (p.H773_V774insH)	N/A	Etoposide+cisplatin	SD	17.2	26.2
16	F	66	Never	1	IIIA	c.2318_2319 ins TAACCCCAG (p.H773_V774insPH)	N/A	Premetrexed+cisplatin	SD	2.8	62.4
17	M	65	Never	1	IA	c.2319_2320insCAC (p.H773_V774insH)	N/A	Premetrexed+cisplatin	PR	2.9	36.9

Sex	Age (yr)	Exon 20 type	ECOG	Smoking history	Initial stage	TKI type	EGFR TKI response	PFS
F	44	Insertion	1	Never-smoker	IV	Erlotinib	PD	0.7
M	65	Insertion	2	Never-smoker	IV	Afatinib	PD	0.9
M	60	Insertion	1	Current smoker 30PY	IV	Erlotinib	PD	2.6
M	48	Insertion	0	Ex-smoker 20PY	IV	Erlotinib	SD	11.4
M	62	Insertion+L858R	1	Ex-smoker 10PY	IIB	Afatinib	PR	1.9
F	43	Insertion+G719S	1	Never-smoker	IV	Osimertinib	PR	2.8

Study	Type of EGFR Exon 20 mutation	Patients treated with EGFR TKIs	ORR to TKI (%)	PFS to TKI	OS
Tu et al. [18]	Insertion 20	12	0	3.0 (1.3-4.7)	12.5 (0-25.5)
Lund-Iversen et al. [13]	Insertion 20	3	0	-	-
Arcila et al. [15]	Insertion 20	5	40	2.5	> 48 mo
Naidoo et al. [12]	Insertion 20	11	27	-	-
Yasuda et al. [17]	Insertion 20	19	11	-	-
Kuiper et al. [19]	Insertion 20	16	0	2.9 (2.3-3.6)	9.7
Current study	Insertion 20	4	25	2.6 (0.7-11.4)	29.4 (9.3-49.6)

Table 1. Clinical characteristics of total 3,539 patients with NSCLC

Values are presented as median (range) or number (%). NSCLC, non-small cell lung cancer; NS, non-significant; ADC, adenocarcinoma; SqCC, squamous cell carcinoma.

Table 2. Baseline characteristics of patients with an exon 20 insertion mutation

Table 3. Amino acid sequences of 17 NSCLC patients with an exon 20 insertion

The most frequent amino acid change was His773_Val774insHis (41.1%), followed by Val774_Cys775insHisVal (17.6%) and His773_Val774insProHis (11.7%).

Table 4. Clinical information and treatment outcomes of six patients who received EGFR TKIs

Table 5. Published studies evaluating clinical response to EGFR TKIs in NSCLC patients with exon 20 insertion

EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression free survival; OS, overall survival.